
-
Replimune Group Inc NasdaqGS:REPL Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Location: 500 Unicorn Park Drive, Woburn, MA, 01801, United States | Website: https://www.replimune.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
144.1M
Cash
536.5M
Avg Qtr Burn
-46.17M
Short % of Float
17.29%
Insider Ownership
4.61%
Institutional Own.
-
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
RP1 +Opdivo (nivolumab) Details Cancer, Melanoma | PDUFA Approval decision | |
RP2 + Opdivo Details Cancer, Uveal melanoma | Phase 2/3 Data readout | |
RP1 + Opdivo Details Cancer, Non-melanoma skin cancer | Phase 2 Update | |
RP1 + Libtayo (cemiplimab) Details Cutaneous squamous cell carcinoma, Cancer | Phase 2 Update | |
RP2 in comb w/ atezolizumab and bevacizumab Details Cancer, Hepatocellular carcinoma | Phase 2 Initiation | |
RP1 Details Cancer, Cutaneous squamous cell carcinoma, Kidney transplantation, Liver transplant, Skin cancer | Phase 1/2 Data readout | |
RP2 +/- Opdivo Details Solid tumor/s, Cancer, Breast cancer, Head and neck cancer, Lung cancer, Hepatocellular carcinoma | Phase 1 Update | |
(RP3 & RP2) in comb w/atezolizumab and bevacizumab Details Cancer, Colorectal cancer , Hepatocellular carcinoma | Failed Discontinued | |
RP3 +/- Opdivo Details Solid tumor/s, Cancer, Lung cancer, Breast cancer, Head and neck cancer | Failed Discontinued | |
RP3 in comb w/std. of care Details Cancer, Head and neck squamous cell carcinoma | Failed Discontinued |